In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Integra LifeSciences shows a significant implied upside of nearly 70% with high valuation confidence, driven mainly by DCF and sales-based models. Despite strong liquidity, profitability and efficiency scores are minimal, highlighting operational challenges. Monte Carlo analysis indicates high volatility but limited downside risk below the current price.